ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

ClinicalTrials.gov ID: NCT03052608

Public ClinicalTrials.gov record NCT03052608. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 11:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER

Study identification

NCT ID
NCT03052608
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
296 participants

Conditions and interventions

Interventions

  • Crizotinib Drug
  • Lorlatinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 26, 2017
Primary completion
Mar 19, 2020
Completion
Dec 30, 2028
Last update posted
Nov 24, 2025

2017 – 2028

United States locations

U.S. sites
34
U.S. states
5
U.S. cities
26
Facility City State ZIP Site status
Florida Cancer Specialists Altamonte Springs Florida 32701
Florida Cancer Specialists Brandon Florida 33511
Florida Cancer Specialists Clearwater Florida 33761
Florida Cancer Specialists Gainesville Florida 32605
Florida Cancer Specialists Largo Florida 33770
Florida Cancer Specialists Lecanto Florida 34461
Florida Cancer Specialists Orange City Florida 32763
Florida Cancer Specialists Orlando Florida 32806
Florida Cancer Specialists Spring Hill Florida 34608
Florida Cancer Specialists St. Petersburg Florida 33705
Florida Cancer Specialists Tampa Florida 33607
Florida Cancer Specialists Tavares Florida 32778
Florida Cancer Specialists The Villages Florida 32159
Florida Cancer Specialists Winter Park Florida 32792
Massachusetts Eye and Ear Infirmary Boston Massachusetts 02114
Massachusetts General Hospital Boston Massachusetts 02114
Ophthalmic Consultants of Boston Inc Boston Massachusetts 02114
The William P. Beetham Eye Institute, Joslin Diabetes Center Boston Massachusetts 02215
University of Rochester Cancer Center Pharmacy Rochester New York 14642
University of Rochester Medical Center Rochester New York 14642
Tennessee Oncology, PLLC Dickson Tennessee 37055
Tennessee Oncology, PLLC Franklin Tennessee 37067
Tennessee Oncology, PLLC Gallatin Tennessee 37066
Tennessee Oncology, PLLC Hermitage Tennessee 37076
Tennessee Oncology, PLLC Lebanon Tennessee 37090
Tennessee Oncology, PLLC Murfreesboro Tennessee 37129
Tennessee Oncology, PLLC Nashville Tennessee 37203
The Sarah Cannon Research Institute. Nashville Tennessee 37203
Tennessee Oncology, PLLC Nashville Tennessee 37205
Tennessee Oncology, PLLC Nashville Tennessee 37207
Tennessee Oncology, PLLC Nashville Tennessee 37211
Tennessee Oncology, PLLC Shelbyville Tennessee 37160
Tennessee Oncology, PLLC Smyrna Tennessee 37167
University of Washington Medical Center Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 132 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03052608, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 24, 2025 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03052608 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →